CLEARBRIDGE HEALTH LIMITED
(Company Registration No. 2021001436C)

PURCHASE CONTRACT FOR THE PURCHASE OF THE SINOPHARM COVID-19 VACCINE FOR USE IN SINGAPORE

A. The Purchase Contract

The board of directors (the "**Board**" or the "**Directors**") of Clearbridge Health Limited (the "**Company**" and, together with its subsidiaries, the **"Group"**) is pleased to announce that today, Clearbridge Medical Group Pte. Ltd. ("**CBMG**"), a subsidiary of the Company, has entered into a purchase contract with, among others, China National Biotec Group Company Limited (中国生物技术股份有限公司) ("**CNBG**") and Beijing Institute of Biological Product Co., Ltd. (北京生物制品研究所有限责任公司) ("**BIBP**"), a subsidiary of CNBG to purchase the SARS-CoV-2 Vaccine (Vero Cell), Inactivated or COVID-19 Vaccine (Vero Cell), Inactivated, also known as COVID-19 Vaccine BIBP (the "**Sinopharm COVID-19 Vaccine**") for use in Singapore (the "**Purchase Contract**"). Please refer to Section D of this announcement for more information on the Sinopharm COVID-19 Vaccine.

Under the terms of the Purchase Contract, it is agreed that, among others:

(1) CBMG shall purchase the Sinopharm COVID-19 Vaccine, which is developed and manufactured by BIBP;
(2) the supply of the Sinopharm COVID-19 Vaccine is subject to approval of the relevant regulatory authorities of the People's Republic of China ("**PRC**");
(3) CBMG shall obtain the authorisation for the use of the Sinopharm COVID-19 Vaccine in Singapore and shall be responsible for handling Adverse Events Following Immunisation ("**AEFI**") if any, arising from the usage of the Sinopharm COVID-19 Vaccine as per the laws and regulations of Singapore; and
(4) CBMG shall be responsible for all pharmacovigilance obligations relating to the use of the Sinopharm COVID-19 Vaccine.

B. Health Sciences Authority of Singapore Special Access Route Approval

Medic Surgical Private Limited ("**MSPL**"), a subsidiary of the Company which operates Medic Surgical & Laser Clinic, has been granted approval under the Health Sciences Authority of Singapore's ("**HSA**") Special Access Route ("**SAR**") scheme to import and supply the Sinopharm COVID-19 Vaccine in Singapore (the "**SAR Approval**"). The SAR Approval is valid for a period of six months from 6 July 2021, unless subsequently renewed.

As at the date of this announcement, the SAR scheme applies only to COVID-19 vaccines that are granted Emergency Use List ("**EUL**") by the World Health Organization ("**WHO**") and which have not been authorised under the Pandemic Special Access Route ("**PSAR**") by HSA. The Sinopharm COVID-19 Vaccine, having received EUL from the WHO, qualifies for the SAR scheme.

For more information on the HSA's SAR scheme, please refer to the HSA's website at: ***https://www.hsa.gov.sg/therapeutic-products/register/special-access-routes/SAR-covid19***. For easy reference, please refer to **Annex A** of this announcement for an extract of the conditions for using the SAR, the conditions of which are also applicable to the SAR Approval.

C. Financial Impact on the Group

Barring unforeseen circumstances, the Company expects the Purchase Contract to contribute positively to the revenue of the Group for the current financial year ending 31 December 2021. The Company, however, is unable to quantify such financial impact as the sales uptake of the Sinopharm COVID-19 Vaccine cannot be determined as at the date of this announcement.

The Group is also currently exploring opportunities relating to the Sinopharm COVID-19 Vaccine in other markets and the Company will make further announcements to keep shareholders informed, as and when there are material updates and developments of those opportunities.

Shareholders and potential investors should note that policies in relation to diagnosis and/or detection of the COVID-19 virus, antigens and/or antibodies, as well as the authorisation and use of COVID-19 vaccines, in Singapore and other jurisdictions may change in response to developments in the COVID-19 situation, which continues to evolve rapidly. Shareholders and potential investors are reminded to exercise caution when dealing in the securities of the Company and should consult their stockbrokers, bank managers, solicitors, accountants or other professional advisers if they are in doubt about the actions that they should take.

D. Sinopharm COVID-19 Vaccine

Based on a WHO COVID-19 Vaccine – Explainer document[1] dated 24 May 2021 (the "**WHO Explainer**"), the Sinopharm COVID-19 Vaccine is a form of vaccine categorised as "inactivated vaccines" which is reported to stimulate the body's immune system without risk of causing diseases. Once inactivated viruses are presented to the body's immune system, they stimulate the production of antibodies, which prepares the body to respond to future live SARS-CoV-2 infections. In addition, the WHO Explainer had also cited the results of a large multi-country phase 3 trial which has shown that two doses of the Sinopharm COVID-19 Vaccine, administered at an interval of 21 days, had the efficacy of 79% against symptomatic SARS-CoV-2 infection 14 days or more after the second dose. **Please note that the Sinopharm COVID-19 Vaccine does not guarantee full immunity against COVID-19**.

As at the date of this announcement, the Sinopharm COVID-19 Vaccine has been authorised for use in several countries including the People's Republic of China, the United Arab Emirates, Malaysia, Thailand and Indonesia.

E. Directors' Declaration

Save for their respective shareholdings in the Company (if any), the Company is not aware of any of its Directors or substantial shareholders having any interest, direct or indirect in the Purchase Contract.

BY ORDER OF THE BOARD

Yee Pinh Jeremy
Executive Director and Chief Executive Officer
9 August 2021

[1] Source: https://www.who.int/publications/m/item/sinopharm-vero-cell---inactivated-covid-19-vaccine

This announcement has been prepared by the Company and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "Sponsor"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited ("SGX-ST") Listing Manual Section B: Rules of Catalist. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr David Tham, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.

Annex A

Conditions for using the SAR

This SAR for licensed healthcare institution ("**HCI**") to import and supply non-PSAR authorised vaccines that are granted EUL by WHO remains in force until such time as HSA's PSAR authorisation for COVID-19 vaccines in Singapore ceases.

It is subject to the following conditions:

1. The application is made by licensed HCI and registered medical practitioners, hereinafter referred to as the "applicant", for their patients who require an alternative COVID-19 vaccine to the currently authorised vaccines by the HSA under the PSAR;

2. The application is made only for the import and supply of vaccines approved under the WHO EUL as at the date of the application and procured from WHO EUL-approved manufacturing sources only;

3. The vaccines must be used according to WHO EUL's approved age groups and indications;

4. The total quantity requested in the application must not exceed the total number of doses required for a maximum supply period of 3 months by the applicant;

5. The SAR approval to import the WHO EUL vaccines in Singapore is valid for a period of 6 months from the date of approval;

6. The applicant must undertake that he is fully aware of the associated risks and takes full responsibility for using the vaccines on the patients under his care. The risks include:

    - The vaccines have not been evaluated for the required quality, safety and efficacy standards for import and supply in Singapore by HSA; and
    - The vaccines are not subject to HSA's enforcement and compliance checks on whether they are adulterated, counterfeit or substandard.

7. The applicant must, upon becoming aware of any serious adverse reaction* arising from the use of the vaccines, report the serious adverse reaction to HSA immediately in no later than 15 days;

8. The applicant must obtain signed informed consents from the patients, and ensure that patients acknowledge the following:

    - The patients have discussed the risks and benefits of using vaccines not authorised by HSA with their doctor, and accept all responsibility for the risks described in paragraph 6; and
    - The patients are aware of Ministry of Health (MOH)'s directive that they will not be eligible for the Vaccine Injury Financial Assistance Programme for COVID-19 Vaccination (VIFAP) should any serious adverse events occur; and may not be treated in the same manner as those vaccinated with PSAR-authorised vaccines for the purpose of public health measures such as travellers and pre-event testing concessions.

9. The applicant must comply with MOH's instructions on the following:

- The recipients of the unauthorised vaccine must be notified to the National Immunisation Registry as soon as possible within 72 hours, with information on the brand name and batch number of the vaccine administered; and
- The applicant must furnish information on the vaccination brand, vaccination sites and start date of vaccination to MOH.

**Serious adverse reactions which: (i) are life-threatening or fatal, (ii) require in-patient hospitalisation or prolong existing hospitalisation, (iii) cause persistent incapacity or disability, (iv) cause birth defect, or, (v) are assessed to be medically significant that may jeopardise the person's health or may require intervention to prevent the person's death or one of the other outcomes in (ii) to (iv).*